Tempest Therapeutics, Inc. (TPST), Wednesday announced clinical data from the ongoing REDEEM-1 Phase 1/2a trial evaluating TPST-2003, a CD19/BCMA dual-targeting CAR-T therapy for patients with relapsed/refractory multiple myeloma.
Patients in the trial experienced no Grade three or higher cytokine release syndrome. Meanwhile, one patient treated at the highest dose level experienced low-grade immune effector cell-associated neurotoxicity syndrome.
The company added that the results of the ongoing REDEEM-1 study are consistent with prior clinical results, including a 24-patient Phase 1/2 IIT, which showed overall response rate of 100 percent, and complete response rate of 89.5 percent.
Tempest plans to present the complete results from the ongoing Phase 1/2a REDEEM-1 study, as well as updated data from the Phase 1/2 IIT, in 2026.
Based on data generated so far, the company intends to submit a U.S. IND application and, subject to clearance, initiate a U.S. registrational study of TPST-2003 in 2026.
In the pre-market, Tempest's stock is trading at $2.4, down 3.61 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.